Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.90 USD
+0.02 (2.51%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.90 0.00 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.90 USD
+0.02 (2.51%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.90 0.00 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -63.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lineage Cell (LCTX) Tops Q4 Earnings Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of 120.00% and -73.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Lineage Cell Therapeutics (LCTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.
Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y
by Zacks Equity Research
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.
Is Lineage Cell Therapeutics (LCTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LCTX) Outperforming Other Medical Stocks This Year?
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.
Will Lineage Cell Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Lineage Cell Therapeutics
Earnings Preview: Lineage Cell (LCTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lineage Cell Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Lineage Cell Therapeutics, Inc. (LCTX) has been struggling lately, but the selling pressure may be coming to an end soon.
Aytu BioScience (AYTU) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Aytu BioScience (AYTU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of 57.14% and 108.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -39.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?